Blood-based neurochemical diagnosis of vascular dementia: A pilot study

Journal of Neurochemistry

Volumn 103, Issue 2, 2007, Pages 467-474

  Bibl, Mirko ^a   Esselmann, Hermann ^b   Mollenhauer, Brit ^c   Weniger, Godehard ^a   Welge, Volker ^a   Liess, Michael ^a   Lewczuk, Piotr ^b   Otto, Markus ^d   Schulz, Jörg B ^a   Trenkwalder, Claudia ^a   Kornhuber, Johannes ^b   Wiltfang, Jens ^b  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d UNIVERSITY OF ULM   (Germany)

Author keywords

Alzheimer's disease; Amyloid peptides; Biomarkers; Plasma; Vascular dementias

Indexed keywords

AMYLOID BETA PROTEIN; BIOLOGICAL MARKER; TAU PROTEIN;

ADULT; AGED; ARTICLE; CEREBROSPINAL FLUID; CEREBROVASCULAR DISEASE; CONTROLLED STUDY; DEPRESSION; DIAGNOSTIC ACCURACY; DIFFERENTIAL DIAGNOSIS; FEMALE; HUMAN; IMMUNOBLOTTING; IMMUNOPRECIPITATION; MAJOR CLINICAL STUDY; MALE; MULTIINFARCT DEMENTIA; NEUROCHEMISTRY; PARKINSON DISEASE; PILOT STUDY; PLASMA; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL;

AGED; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; BIOLOGICAL MARKERS; CEREBROVASCULAR DISORDERS; DEMENTIA; DEMENTIA, VASCULAR; DEPRESSIVE DISORDER; DIAGNOSIS, DIFFERENTIAL; ELECTROPHORESIS, POLYACRYLAMIDE GEL; FEMALE; HUMANS; MALE; MIDDLE AGED; PARKINSON DISEASE; PEPTIDE FRAGMENTS; PILOT PROJECTS; TAU PROTEINS;

EID: 34848839945     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2007.04763.x     Document Type: Article

References (30)

1. Bibl M., Esselmann H., Otto M., Lewczuk P., Cepek L., Rüther E. Kornhuber J. (2004) Cerebrospinal fluid (CSF) amyloid beta (Aβ) peptide patterns in Alzheimer's disease (AD) patients and non-demented controls depend on sample pre-treatment: Indication of carrier- mediated epitope masking of Aβ peptides. Electrophoresis 25, 2912 8.
2. Bibl M., Mollenhauer B., Esselmann H. et al. (2006) CSF amyloid-β-peptides in Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease dementia. Brain 129, 1177 1187.
3. Bibl M., Mollenhauer B., Lewczuk P. et al. (2007) Validation of amyloid-β peptides in CSF diagnosis of neurodegenerative dementias. Mol. Psy. 12, 671 680.
4. Blennow K. (2004) Cerebrospinal Fluid Protein Biomarkers for Alzheimer's disease. NeuroRX 1, 213 225.
5. Fischer P., Jellinger K., Gatterer G. Danielczyk W. (1991) Prospective neuropathological validation of Hachinski's ischaemic score in dementias. J. Neurol. Neurosurg. Psychiatry 7, 580 583.
6. Fukumoto H., Tennis M., Locascio J. J., Hyman B. T., Growdon J. H. Irizarry M. C. (2003) Age but not diagnosis is the main predictor of plasma amyloid β-protein levels. Arch. Neurol. 60, 958 964.
7. Gibb W. R. Lees A. J. (1988) The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 51, 745 752.
8. Gravina S. A., Ho L., Eckman C. B., Long K. E., Otvos L. Jr., Younkin L. H., Suzuki N. Younkin S. G. (1995) Amyloid β protein in Alzheimer's diesease brain. J. Biol. Chem. 270, 7013 7016.
9. Güntert A., Döbeli H. Bohrmann B. (2006) High sensitivity analysis of Amyloid-beta peptide composition in amyloid deposits from human and PS2APP mouse brain. Neuroscience 143, 461 475.
10. Gurol M. E., Irizarry M. C., Smith E. E., Raju S., Diaz-Arrastia R., Bottiglieri T., Rosand J., Growdon J. H. Greenberg S. M. (2006) Plasma β-amyloid and white matter lesions in AD, MCI and cerebral amyloid angiopathy. Neurology 66, 23 29.
11. Hulstaert F., Blennow K., Ivanoiu A. et al. (1999) Improved discrimination of AD-patients using ß-amyloid (1-42) and tau levels in CSF. Neurology 52, 1555 1562.
12. Irizarry M. C. (2004) Biomarkers of Alzheimer disease in plasma. NeuroRX 1, 226 234.
13. Janek K., Rothemund S., Gast K., Beyermann M., Zipper J., Fabian H., Bienert M. Krause E. (2001) Study of the conformational transition of A beta(1-42) using D-amino acid replacement analogues. Biochemistry 40, 5457 5463.
14. Lewczuk P., Esselmann H., Bibl M. et al. (2004) Electrophoretic separation of amyloid β (Aβ) peptides in plasma. Electrophoresis 25, 3336 3343.
15. Loeb C. Meyer J. S. (1996) Vascular dementia: still a debatable entity?. J. Neurol. Sci. 143, 31 40.
16. McKeith I. G., Galasko D., Kosaka K. et al. (1996) Consensus guidlines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 47, 1113 1124.
17. McKhann G., Drachman D., Folstein M., Katzmann R., Price D. Stadlan E. M. (1984) Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34, 939 944.
18. Mehta P. D. Pirttila T. (2005) Increased cerebrospinal fluid A bata38/A beta42 in Alzheimer disease. Neurodegener. Dis. 2, 242 245.
19. Mollenhauer B., Cepek L., Bibl M. et al. (2006) Aβ1-42 and tau protein in cerebrospinal fluid of patients with Parkinson's disease dementia. Dement. Geriatr. Cogn. Disord. 22, 200 208.
20. O'Brien J. T., Erkinjutti T., Reisberg B. et al. (2003) Vascular cognitive impairment. Lancet Neurol. 2, 89 97.
21. Pomara N., Doraiswamy P. M., Willoughby L. M., Roth A. E., Mulsant B. H., Sidtis J. J., Mehta P. D., Reynolds C. F. Pollock B. G. (2006) Elevation in plasma Abeta42 in geriatric depression: a pilot study. Neurochem. Res. 31, 341 349.
22. Roman G. C., Tatemichi T. K., Erkinjutti T., Cummings J. L., Masdeu J. C., Garcia J. H., Amaducci L., Orgogozo J. M., Brun A. Hofmann A. (1993) Vascular dementia: diagnostic criteria for research studies: report of the NINDS-AIREN International Workshop. Neurology 43, 243 245.
23. Schoonenboom N. S., Mulder C., Van Kamp G. J., Mehta S. P., Scheltens P., Blankenstein M. A. Mehta P. D. (2005) Amyloid β 38, 40 and 42 species in cerebrospinal fluid: More of the same?. Ann. Neurol. 58, 139 142.
24. Van Oijen M., Hofmann A., Soares H. D., Koudstaal P. J. Breeteler M. M. B. (2006) Plasma Aβ1-40 and Aβ1-42 and the risk of dementia: a prospective case-cohort study. Lancet Neurol. 5, 655 660.
25. Weggen S., Eriksen J. L., Das P. et al. (2001) A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. Nature 414, 212 216.
26. Wiltfang J., Esselmann H., Cupers P. et al. (2001) Elevation of β-amyloid peptide 2-42 in sporadic and familial Alzheimer's Disease and its generation in PS1 knockout cells. J. Biol. Chem. 276, 426745 42657.
27. Wiltfang J., Esselmann H., Bibl M. et al. (2002) Highly conserved and disease-specific patterns of carboxyterminally truncated Abeta peptides 1-37/38/39 in addition to 1-40/42 in Alzheimer's disease and patients with chronic neuroinflammation. J. Neurochem. 81, 481 496.
28. Wiltfang J., Esselmann H., Bibl M. et al. (2007) Amyloid beta peptide ratio 42/40 but not Abeta42 corelates with phospho-Tau in patients with low- and high CSF-Abeta40 load. J. Neurochem. 101, 1053 1059.
29. World Medical Organisation. (1996) Declaration of Helsinki. Br. Med. J. 313, 1448 1449.
30. Yoshimoto M., Iwai A., Kang D., Otero D. A., Xia Y. Saitoh T. (1995) NACP, the precursor of the non-amyloid beta/A4 protein (A beta) component of Alzheimer disease amyloid, binds A beta and stimulates A beta aggregation. Proc. Natl Acad. Sci. USA 92, 9141 9145.